Platelet-rich Plasma-derived Exosomes as Novel Frontier in Regenerative Medicine

Abstract: Regenerative medicine is a relatively new field that has been utilized recently to address specific problems by harnessing the body';s molecular composition. Platelet-rich plasma (PRP) is an autologous blood product with a high concentration of platelets, which further releases two important growth factors: Transforming Growth Factor-Beta (TGF-β) and Platelet-Derived Growth Factor (PDGF), responsible for tissue regeneration and repair. PRP contains small extracellular vesicles known as exosomes, which enhance cell-to-cell communication by delivering lipids, proteins, and nucleotides to the target cells. This dual mechanism enhances the therapeutic potential of PRP by stimulating cell proliferation, angiogenesis, and immunological regulation. Exosomes derived from PRP have been investigated for potential applications in cancer, orthopedics, wound healing, and dermatology. They have shown promising results in decreasing inflammation, promoting bone and cartilage regeneration, reshaping tumor microenvironments, and accelerating tissue repair. To enhance their clinical application, advanced isolation and characterization methods, such as size exclusion chromatography and ultracentrifugation, are required to further characterize their nature and facilitate downstream purification. A couple of lingering concerns, aside from the advantages of standardizing the isolation procedure, include regulatory hurdles. Future research aims to refine PRP exosome applications through the identification of biomarkers and the development of combination therapies. With further advancements, PRP-derived exosomes could revolutionize regenerative medicine, offering a targeted, non-invasive, and highly effective treatment modality for various medical conditions.